Roche to acquire liver drug developer 89bio for up to $3.5 billion

Roche RO said on Thursday it agreed to acquire U.S. biotech firm 89bio

In a statement, the Swiss drugmaker said the deal was worth about $2.4 billion, or up to $3.5 billion when including a non-tradeable contingent value right.